Status:
RECRUITING
A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
Lead Sponsor:
Peking University People's Hospital
Conditions:
Ablation
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Although surgical resection is the gold standard for early breast cancer treatment, some patients cannot tolerate surgery due to medical conditions or refuse surgical treatment for cosmetic reasons. I...
Detailed Description
1\. Study Design 1. Prospective Cohort Study Study Subjects and Selection Criteria 2. This study is based on the breast disease cohort database of Peking University People's Hospital Breast Center. P...
Eligibility Criteria
Inclusion Criteria:
- 1) Aged 18 or above; 2) Breast cancer confirmed by core needle biopsy; 3) Tumor lesions clearly visible on ultrasound; 4) No contraindications for cryoablation such as coagulation disorders; 5) Presence of reasons unsuitable for conventional surgical resection: patient's condition cannot tolerate general anesthesia or surgical treatment; due to unresectable and/or metastatic disease; patient refuses surgery, etc.; 6) Agree to undergo ablation surgery and sign the consent form.
Exclusion Criteria:
- 1) Missing clinical and pathological data (such as imaging and pathological materials); 2) Pregnant or lactating women; 3) Known allergies, intolerances, or contraindications to cryotherapy (such as cryoglobulinemia, presence of implanted electronic devices); 4) Vulnerable populations, including those with neurological disorders, cognitive impairments, critically ill patients, etc.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07238894
Start Date
December 1 2025
End Date
October 1 2028
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China, 100000